RecruitingNCT02169518

Paraoxonase and HDL Qualities in Glycaemia and Inflammation

Changes in Paraoxonase Activity, HDL Properties, Inflammatory Markers and Corneal Innervation in Post-bariatric Surgery Patients, Type 1 Diabetics With and Without Nephropathy, Type 2 Diabetics, and During an Oral Glucose Tolerance Test.


Sponsor

Manchester University NHS Foundation Trust

Enrollment

600 participants

Start Date

Jul 5, 2012

Study Type

OBSERVATIONAL

Conditions

Summary

The incidence of coronary heart disease (CHD) is significant in the super-obese and diabetics. Inflammation is believed to play an important part in the development of CHD, and the large collection of abdominal fat in the obese person is a vast source of inflammation. Diabetics have abnormal glucose and cholesterol metabolism which ultimately compromise their bodies' circulatory system and nerve function. Cholesterol plays a vital role in CHD. Low-density lipoprotein (LDL) particles carry cholesterol and deposit it in blood vessel walls which become damaged as a result. When LDL particles undergo changes chemically (called oxidation) or as a result of high circulating blood glucose (called glycation), they become more harmful to the body. High-density lipoprotein (HDL) particles have a protective function in CHD. Not only do they transport cholesterol away from the blood vessels to the liver to be broken down, they have properties against oxidation and inflammation. These properties are related to the activity of an enzyme on HDL called paraoxonase 1(PON1). Super-obese patients are increasingly treated by weight-reducing surgery (bariatric surgery). In this study we examine whether weight loss following bariatric surgery results in reduced inflammatory state, improved HDL function (higher PON1 activity), better control of blood glucose and less nerve damage. We will study PON1 activity, inflammation and glucose control in patients with type 1 diabetes (with and without kidney damage) and type 2 diabetes. We will also study the effects of rapidly rising blood glucose levels on PON1 and glycated LDL in patients undergoing oral glucose tolerance test.


Eligibility

Min Age: 20 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is examining a liver-made enzyme called paraoxonase and certain properties of HDL ("good") cholesterol in people with diabetes and related conditions, to understand how these factors relate to inflammation and heart disease risk in diabetic patients. **You may be eligible if...** - You have type 1 or type 2 diabetes without signs of heart disease, and are not taking certain medications (fish oil supplements or thiazolidinediones) - You have impaired fasting glucose (prediabetes) being tested with an oral glucose tolerance test - You are scheduled for weight-loss (bariatric) surgery - You are a healthy person aged 20–75 with no serious illness and not taking regular medications - You are able to give informed consent **You may NOT be eligible if...** - You have a history of heart disease or ECG changes suggesting heart disease - You are taking certain blood fat–lowering medications or fish oil supplements (in some groups) - You are a healthy person with a history of diabetes or vascular disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Central Manchester University Hospitals NHS Foundatioon Trust

Manchester, Lancashire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02169518


Related Trials